A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

NCT06916065 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and effects of the experimental drug eloralintide, alone and combined with tirzepatide, in adults who are overweight or have obesity.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) basic-science study

Participants 188 people

Who can join Ages 18–65 · all sexes

Timeline Started 2025-04 · est. completion 2026-01

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT06916065 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much eloralintide and eloralintide with tirzepatide get into the bloodstream and how long it takes the body to eliminate it. There will be 6 cohorts. The study will last up to approximately 26 weeks, excluding screening for Cohorts A and B, 11 weeks for Cohorts C and D, and 12 weeks for Cohorts E and F.

Treatments tested

Eloralintide and Tirzepatide also known as LY3841136 Drug

Administered SC
Eloralintide also known as LY3841136 Drug

Administered SC

Main thing measured	Cohorts A and B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Eloralintide and Tirzepatide
Sponsor	Eli Lilly and Company
Conditions studied	Overweight, Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06916065 ↗